Literature DB >> 10794357

P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients.

S Khaliq1, A Hameed, T Khaliq, Q Ayub, R Qamar, A Mohyuddin, K Mazhar, S Qasim-Mehdi.   

Abstract

Inactivation of the p53 gene has been found to be associated with the pathogenesis of several neoplasias. Three biallelic polymorphisms in the p53 gene have been linked to predisposition to the development of various malignancies. These include a 16-bp duplication in intron 3 and BstU I and Msp I restriction fragment length polymorphisms (RFLPs) in exon 4 and intron 6, respectively. The prevalence of these polymorphisms was studied in breast cancer patients and nine major ethnic groups of Pakistan. Differences in allele frequencies for all three polymorphisms were observed among the various ethnic groups and breast cancer patients. The absence of the 16-bp duplication was common among the northern ethnic groups, being highest in the Hazara (0.90). The Msp I A1 allele frequency in the southern Makrani population was significantly higher in comparison with the other ethnic groups. In the cancer patients, the absence of the 16-bp duplication in combination with the BstU I Pro and absence of Msp I restriction site were the most frequent. In these patients, ten substitution mutations were found in the p53 gene, seven of which have been reported previously for breast cancer. The remaining three mutations have been found in other malignancies, but not in carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794357     DOI: 10.1089/109065700316435

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  12 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude.

Authors:  A V Khrunin; L A Tarskaia; V A Spitsyn; O I Lylova; N A Bebyakova; A I Mikulich; S A Limborska
Journal:  Mol Genet Genomics       Date:  2005-01-15       Impact factor: 3.291

3.  TP53 codon 72 polymorphism in 12 populations of insular Southeast Asia and Oceania.

Authors:  Taeko Kashima; Kumiko Makino; Augustinua Soemantri; Takafumi Ishida
Journal:  J Hum Genet       Date:  2007-07-03       Impact factor: 3.172

4.  p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.

Authors:  Shuting Jia; Wenru Tang; Ying Luo
Journal:  Hepatol Int       Date:  2012-08-03       Impact factor: 6.047

5.  Association of specific genotype and haplotype of p53 gene with cervical cancer in India.

Authors:  S Mitra; C Misra; R K Singh; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

6.  Novel p53 codon 240 Ser > Thr coding region mutation in the patients of oral squamous cell carcinoma (OSCC).

Authors:  S Saleem; Z A Abbasi; A Hameed; N R Qureshi; M A Khan; A Azhar
Journal:  Tumour Biol       Date:  2014-05-16

Review 7.  Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.

Authors:  Roman Hrstka; Philip J Coates; Borivoj Vojtesek
Journal:  J Cell Mol Med       Date:  2009-03       Impact factor: 5.310

8.  Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population.

Authors:  Chaymaa Marouf; Amal Tazzite; Brehima Diakité; Hassan Jouhadi; Abdellatif Benider; Sellama Nadifi
Journal:  Tumour Biol       Date:  2014-09-09

9.  p53 codon 72 polymorphism and breast cancer risk: A meta-analysis.

Authors:  Jing Hou; Yuan Jiang; Wenru Tang; Shuting Jia
Journal:  Exp Ther Med       Date:  2013-03-20       Impact factor: 2.447

10.  Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.

Authors:  Luca Cavallone; Suzanna L Arcand; Christine Maugard; Parviz Ghadirian; Anne-Marie Mes-Masson; Diane Provencher; Patricia N Tonin
Journal:  BMC Cancer       Date:  2008-04-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.